HIV infection and pulmonary arterial hypertension

Expert Review of Respiratory Medicine

Volumn 5, Issue 2, 2011, Pages 257-266

  Cicalini, Stefania ^a   Chinello, Pierangelo ^a   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

antiretroviral therapy; bosentan; clinical; diagnosis; epidemiology; HIV; pathogenesis; pulmonary arterial hypertension; sildenafil; treatment

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMBRISENTAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CHEMOKINE RECEPTOR CXCR4; COCAINE; DIGOXIN; DIURETIC AGENT; ENDOTHELIN 1; GLYCOPROTEIN GP 120; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; NEF PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; RITONAVIR; SAQUINAVIR; SILDENAFIL; SITAXSENTAN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNIPROST; VASODILATOR AGENT; WARFARIN;

CATHETER INFECTION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; GENE MUTATION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMIC MONITORING; HEMODYNAMICS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXEMIA; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MOLECULAR GENETICS; MORTALITY; OXYGEN THERAPY; PATHOGENESIS; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; VASOCONSTRICTION; VENOUS THROMBOEMBOLISM;

EID: 79955386591     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.10     Document Type: Review

References (84)

1. Petrosillo N. Pulmonary vascular disease and infection: a tale of two diseases. Clin. Microbiol. Infect. DOI: 10.1111/j.1469-0691.2010.03291.x (2010) (Epub ahead of print).
2. Opravil M, Pechère M, Speich R et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am. J. Respir. Crit. Care Med. 155, 990-995 (1997).
3. Hsue PY, Deeks SG, Farah HH et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 22(7), 825-833 (2008). (Pubitemid 351563831)
4. Humbert M, Sitbon O, Chaout A et al. Pulmonary arterial hypertension in France. Am. J. Respir. Crit. Care Med. 173, 1023-1030 (2006).
5. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 100, 1268-1271 (1991).
6. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 22, 35-40 (2008).
7. Sitbon O, Lascoux-Combe C, Delfraissy JF et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am. J. Respir. Crit. Care Med. 177, 108-113 (2008).
8. Zuber JP, Calmy A, Evison JM et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin. Infect. Dis. 38, 1178-1185 (2004). (Pubitemid 38951268)
9. Cicalini S, Chinello P, Cicini MP, Petrosillo N. Pulmonary arterial hypertension and HIV infection. AIDS 22, 2219-2220 (2008).
10. Himelman RB, Dohrmann M, Goodman P et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am. J. Cardiol. 64, 1396-1399 (1989). (Pubitemid 20000102)
11. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 118, 1133-1141 (2000).
12. Nunes H, Humbert M, Sitbon O et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 167, 1433-1439 (2003). (Pubitemid 36609730)
13. Degano B, Guillaume M, Savale L et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 24, 67-75 (2010).
14. Petitpretz P, Brenot F, Azarian R et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 89, 2722-2777 (1994).
15. Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann. NY Acad. Sci. 946, 82-94 (2001).
16. Mette SA, Palevsky HI, Pietra GG et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am. Rev. Respir. Dis. 145, 1196-1200 (1992).
17. Humbert M, Monti G, Fartoukh M et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J. 11, 554-559 (1998). (Pubitemid 28194842)
18. Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and HIV infection: epidemiology, pathogenesis, and clinical approach. Clin. Microbiol. Infect. DOI: 10.1111/j.1469-0691.2010.03286.x (2010) (Epub ahead of print).
19. Marecki JC, Cool CD, Voelkel N, Luciw P, Flores S. Evidence for vascular remodeling in the lungs of macaques infected with simian immunodeficiency virus/HIV NEF recombinant virus. Chest 128, 621S-622S (2005). (Pubitemid 43054171)
20. Marecki JC, Cool CD, Parr JE et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-Nef-infected macaques. Am. J. Respir. Crit. Care Med. 174, 437-445 (2006). (Pubitemid 44223125)
21. Flores SC, Almodovar S. HIV-1 Nef signature sequences and pulmonary arterial hypertension: structure-function relationships to pathogenesis. FASEB J. 23(Meeting Abstract Suppl.), 331.1 (2009).
22. Roeth JF, Collins KL. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol. Mol. Biol. Rev. 70, 648-563 (2006).
23. Sehgal PB, Mukhopadhyay S, Patel K et al. Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-Nef-infected macaques. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L729-L737 (2009).
24. Hassoun PM, Mouthon L, Barberà JA et al. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54, S10-S19 (2009).
25. Olivetta E, Percario Z, Fiorucci G et al. HIV-1 Nef induces the release of inflammatory factors from human monocytes/macrophages: involvement of Nef endocytotic signals and NF-kB activation. J. Immunol. 170, 1716-1727 (2003). (Pubitemid 36197386)
26. Kim J, Ruff M, Karwatowska-Prokopczuk E et al. HIV envelope protein gp120 induces neuropeptide Y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul. Pept. 75-76, 201-205 (1998). (Pubitemid 28477528)
27. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem. Biophys. Res. Commun. 333, 1107-1115 (2005). (Pubitemid 40910118)
28. Raidel SM, Haase C, Jansen NR et al. Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am. J. Physiol. Heart Circ. Physiol. 282, H1672-H1678 (2002). (Pubitemid 34654834)
29. Fiala M, Popik W, Qiao JH et al. HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signalling. Cardiovasc. Toxicol. 4, 97-107 (2004). (Pubitemid 39310744)
30. Salvi SS. a1-adrenergic hypothesis for pulmonary hypertension. Chest 115, 1708-1719 (1999).
31. Semenza GL. Transcriptional regulation by hypoxia-inducible factor-1: molecular mechanisms of oxygen homeostasis. Trends Cardiovasc. Med. 6, 151-157 (1996). (Pubitemid 26256220)
32. Semenza GL. Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Chest 128, 592S-594S (2005). (Pubitemid 43054145)
33. Tipoe GL, Lau TY, Nanji AA, Fung ML. Expression and functions of vasoactive substances regulated by hypoxia-inducible factor-1 in chronic hypoxemia. Cardiovasc. Hematol. Agents Med. Chem. 4, 199-218 (2006). (Pubitemid 44054828)
34. Nakamura K, Fujio H. Are adrenergic receptor blockers effective or contraindicated in pulmonary arterial hypertension? Circ. J. 73, 2212-2213 (2009).
35. Provencher S, Herve P, Jais X et al. Deleterious effects of b-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130, 120-126 (2006). (Pubitemid 43049842)
36. Cool CD, Rai PR, Yeager ME et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N. Engl. J. Med. 349, 1113-1122 (2003). (Pubitemid 37122323)
37. Henke-Gendo C, Schulz TF, Hoeper MM. HHV-8 in pulmonary hypertension. N. Engl. J. Med. 350, 194-195 (2004).
38. Gutierrez F, Masia M, Padilla S et al. Occult lymphadenopathic Kaposi's sarcoma associated with severe pulmonary hypertension: a clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension? J. Clin. Virol. 37, 79-82 (2006). (Pubitemid 44441970)
39. Laney AS, De Marco T, Peters JS et al. Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest 127, 762-767 (2005). (Pubitemid 40775503)
40. Katano H, Ito K, Shibuya K, Saji T, Sato Y, Sata T. Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. J. Infect. Dis. 191, 743-745 (2005). (Pubitemid 40271063)
41. Daibata M, Miyoshi I, Taguchi H et al. Absence of human herpesvirus 8 in lung tissues from Japanese patients with primary pulmonary hypertension. Respir. Med. 98, 1231-1232 (2004). (Pubitemid 39497227)
42. Bendayan D, Sarid R, Cohen A, Shitrit D, Shechtman I, Kramer MR. Absence of human herpesvirus 8 DNA sequences in lung biopsies from Israeli patients with pulmonary arterial hypertension. Respiration 75, 155-157 (2008). (Pubitemid 351363868)
43. Galambos C, Montgomery J, Jenkins FJ. No role for Kaposi Sarcoma-associated herpesvirus in pediatric idiopathic pulmonary hypertension. Pediatr. Pulmonol. 41, 122-125 (2006). (Pubitemid 43165439)
44. Nicastri E, Vizza CD, Carletti F et al. Human herpesvirus 8 and pulmonary hypertension. Emerg. Infect. Dis. 11, 1480-1482 (2005). (Pubitemid 41209154)
45. Valmary S, Dorfmuller P, Montani D, Humbert M, Brousset P, Degano B. Human g-herpesviruses EBV and HHV-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension. Chest DOI: 10.1378/chest.10-1200 (2010) (Epub ahead of print).
46. Morse JH, Barst RJ, Itescu S et al. Primary pulmonary hypertension in HIV infection. An outcome determined by particular HLA class II alleles. Am. J. Respir. Crit. Care Med. 153, 1299-1301 (1996).
47. Sztrymf B, Coulet F, Girerd B et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am. J. Respir. Crit. Care Med. 177, 1377-1383 (2008). (Pubitemid 351860916)
48. Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. HIV-1 Tat represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J. Leukoc. Biol. 79, 192-201 (2006). (Pubitemid 43054265)
49. Degano B, Sitbon O, Simonneau G. Pulmonary arterial hypertension and HIV infection. Semin. Respir. Crit. Care. Med. 30, 440-447 (2009).
50. Budhiraja R, Hassoun PM. Portopulmonary hypertension. A tale of two circulations. Chest 123, 562-576 (2003). (Pubitemid 36269445)
51. Kuddus RH, Nalesnik MA, Subbotin VM, Rao AS, Gandhi CR. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes -an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J. Hepatol. 33, 725-732 (2000).
52. Gandhi CR, Kang Y, De Wolf A et al. Altered endothelin homeostasis in patients undergoing liver transplantation. Liver Transplant. Surg. 2, 362-369 (1996). (Pubitemid 26303925)
53. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 130, 1657-1663 (2006). (Pubitemid 46033416)
54. Isabelle M, Monteil C, Moritz F et al. Role of a1-adrenoreceptors in cocaine-induced NADPH oxidase expression and cardiac dysfunction. Cardiovasc. Res. 67, 699-704 (2005). (Pubitemid 41033365)
55. Abenhaim L, Moride Y, Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 335, 609-616 (1996). (Pubitemid 26277950)
56. Petrache I, Diab K, Knox KS et al. HIV-associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax 63, 463-469 (2008). (Pubitemid 351692357)
57. Galiè N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur. Heart J. 30, 2493-2537 (2009).
58. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111, 3105-3111 (2005). (Pubitemid 40847788)
59. Confalonieri M, Kodric M, Longo C, Vassallo FG. Bosentan for chronic thromboembolic pulmonary hypertension. Expert Rev. Cardiovasc. Ther. 7, 1503-1512 (2009).
60. Limsukon A, Imran Saeed A, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension. Mt Sinai J. Med. 73, 1037-1044 (2006). (Pubitemid 46040407)
61. Rich S, Seidlitz M, Osimani D et al. The short-term effects of digoxin in patients with right ventricular dysfunciton from pulmonary hypertension. Chest 114, 787-792 (1998). (Pubitemid 28433741)
62. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351, 1425-1436 (2004).
63. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopatological study of 80 cases. Mayo Clin. Proc. 60, 16-25 (1985). (Pubitemid 15199621)
64. Johnson SR, Mehta S, Granton JT. Anticolagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur. Respir. J. 28, 999-1004 (2006). (Pubitemid 46331971)
65. Glesby MJ, Aberg JA, Kendall MA et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin. Pharmacol. Ther. 78, 143-153 (2005). (Pubitemid 41112282)
66. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med. 162, 1846-1850 (2000).
67. Petrosillo N, Viale P, Nicastri E et al. Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. Clin. Infect. Dis. 34, 677-685 (2002). (Pubitemid 34165332)
68. Cea-Calvo L, Escribano Subías P, Tello de Menesses R et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev. Esp. Cardiol. 56, 421-425 (2003). (Pubitemid 36608985)
69. Ghofrani HA, Rose F, Schermuly RT. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42, 158-164 (2003). (Pubitemid 36760778)
70. Sitbon O, Gressin V, Speich R et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 170, 1212-1217 (2004). (Pubitemid 39577380)
71. Degano B, Yaaci A, Le Pavec J et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur. Resp. J. 33, 92-98 (2009).
72. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. 30, 338-344 (2007). (Pubitemid 47194187)
73. Zacà V, Metra M, Danesi R, Lombardi C, Verzura G, Dei Cas L. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Ther. Adv. Respir. Dis. 3, 11-14 (2009).
74. Galiè N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157 (2005). (Pubitemid 41653106)
75. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related hypertension. AIDS 15, 1747-1748 (2001).
76. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 16, 1568-1569 (2002). (Pubitemid 34804229)
77. Wong AR, Rascol AH, Abidin NZ, Noor AR, Quan BS. Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. J. Paediatr. Child Health 42, 147-148 (2006). (Pubitemid 43356872)
78. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol. 50, 99-107 (2000). (Pubitemid 30612027)
79. Pellicelli AM, Palmieri F, D'Ambrosio C et al. Role of human immunodeficiency virus in primary pulmonary hypertension. Case reports. Angiology 49, 1005-1011 (1998). (Pubitemid 29005671)
80. Cicalini S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr. HIV Res. 7, 589-596 (2009).
81. Humbert M. Mediators involved in HIV-related pulmonary arterial hypertension. AIDS 22(Suppl. 3), S41-S47 (2008).
82. Cicalini S, Chinello P, Petrosillo N, Nicastri E. Pulmonary arterial hypertension in HIV-infected patients. Curr. Hypertens. Rev. 4, 131-142 (2008).
83. European Medicines Agency. Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury www.ema.europa.eu/ema/index. jsp?curl=pages/news-and-events/news/2010/12/news-detail-001161. jsp&murl=menus/news-and-events/news-and-events.jsp&mid=WC0b01ac05 8004d5c1&jsenabled=true (Accessed 11 January 2011)
84. Pfizer. Pfizer stops clinical trials of Thelin and initiates voluntary product withdrawal in the interest of patient safety www.pfizer.com/news/press- releases/pfizer-press-releases.jsp (Accessed 11 January 2011)